Sell-side PT & Stock Update on Welltower Inc (NYSE:HCN), Biogen Idec Inc. (NASDAQ:BIIB)

Sell-side PT & Stock Update on Welltower Inc (NYSE:HCN), Biogen Idec Inc. (NASDAQ:BIIB)

The Wall Street analysts who cover Welltower Inc (NYSE:HCN) shares are providing price target projections on the company. They project that the shares will move to $76.5 within the upcoming year. The number they've arrived at is calculated by, long known as a provider of top-notch investment research. From the analysts polled by Zack's Research, the highest estimate stands at $90 and the lowest is at $63 for the stock.

Analyst Ratings In View

Zacks provides the average brokerage recommendation (ABR) for thousands of stocks for institutions and retail investors alike. This the calculated average of the actual recommendations (strong buy, hold, sell etc.) made for a given stock. The ABR is typically displayed with decimals (e.g. 1.52) versus the Zacks Rank, which is only shown in whole numbers (e.g. 1, 2, 3, etc.). This simplifies brokerage recommendations, which can become complicated. Welltower Inc (NYSE:HCN)'s shares currently have an ABR of 2.67.

During this fiscal period, Street analysts are projecting $1.14 earnings/share. This represents the current Zacks consensus EPS. For the period which closed on 2016-06-30, Welltower Inc (NYSE:HCN) dialed in an EPS of $1.15, creating a Surprise Factor of 0.88% (the difference between analyst projections and actual numbers). Curious investors will be awaiting 2016-11-04, the date when Welltower Inc (NYSE:HCN) will release their quarterly results.

Wall Street sell-side research analysts covering Biogen Idec Inc. (NASDAQ:BIIB) shares have recently provided various price target projections on where the stock might be going. According to them, the stock is expected to reach $351.428 on a consensus level within the next year, according to Zacks. The most bullish estimate sees the stock reaching $414 while the most conservative estimate stand at $283.

Zacks also gives an average broker rating based on the sell-side recommendations from the analysts who cover Biogen Idec Inc.. They give the company shares an ABR of 1.83. This is based on the 14 analysts taken into consideration by Zacks.

Earnings Estimates for Biogen Idec Inc. (NASDAQ:BIIB)

Currently, Wall Street is projecting that the firm will post $5.01 earnings per share. This consensus number is also derived from Zacks. For the most recent period which ended on 2016-06-30, Biogen Idec Inc.'s EPS was reported as $5.21. This created a “surprise factor” 11.09% due to being $0.52 apart from what Wall Street predicted. When actual numbers differ greatly from the consensus expectations, sharp movement in the stock price can often be seen in the hours or days following the report.

Investors will mark their calendars for 2016-10-19, the date when Biogen Idec Inc. (NASDAQ:BIIB) are expected to release their quarterly results.